PIK3CA-Related Overgrowth Spectrum (PROS) research hub

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This study is testing a new medicine called RLY-2608 for adults and children with certain conditions where parts of their body have grown too much or developed unusually due to a specific genetic change. It aims to see if the medicine is safe and if it can help improve these conditions.